

S/N 10/018719

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Becker, et al.	Docket No.:	13390.2USWO
Serial No.:	10/018719	Filed:	December 14, 2001
Int'l Appln No.:	PCTEP00005517	Int'l Filing Date:	June 15, 2000
Title:	USE OF GROWTH HORMONE (HGH) FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISTURBANCES		

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EV072823491

Date of Deposit: March 21, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

By: 

Chris Stordahl

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Box PCT

Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. At least some of the references were recently cited in an International Search Report mailed April 25, 2001.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided. Enclosed for the Examiner's information is a copy of the International Search Report.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. In accordance with the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: March 21, 2002

By   
Ronald A. Daigault  
Reg. No. 25,968

RAD/rw

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13390.2USWO	Application Number: 10/018719
	Applicant: Becker, et al.	
	Filing Date: December 14, 2001	Group Art Unit:

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	9842361	1-OCT-2001	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Böger R.H. et al., <u>Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency</u> , J. Clin. Invest. 98: 2706-2713, 1996.
	Burnett A.L. et al., <u>Nitric oxide: a physiologic mediator or penile erection</u> , Science 257: 905, 1993.
	Fujita K, et al., <u>Male sexual insufficiency</u> , Japanese Journal of Clinical Medicine, pgs 2908-13, November 1997.
	Jung G.W. et al., <u>Growth hormone enhances regeneration of nitric oxide synthase-containing penile nerves after cavernous neurotomy in rats</u> , J. Urol. 160: 1899-1904, 1998
	Merimee T.J. and Grant M.B., <u>Growth hormone and its disorders</u> . In: Principles and Practice of Endocrinology and Metabolism, Edited by Becker, K.L., Philadelphia, J.B. Lippincott Company, pp. 125-134, 1990.



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	